Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 18 | 2025 | 625 | 4.590 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2024 | 1105 | 1.340 |
Why?
|
| Mohs Surgery | 6 | 2024 | 28 | 1.260 |
Why?
|
| Dermatology | 6 | 2025 | 46 | 1.210 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2024 | 63 | 1.050 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2017 | 17 | 0.970 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2021 | 53 | 0.960 |
Why?
|
| Neuromuscular Agents | 3 | 2021 | 29 | 0.890 |
Why?
|
| Skin | 6 | 2022 | 605 | 0.830 |
Why?
|
| Cosmetic Techniques | 4 | 2025 | 28 | 0.820 |
Why?
|
| Laser Therapy | 4 | 2025 | 151 | 0.810 |
Why?
|
| Melanoma | 2 | 2024 | 497 | 0.720 |
Why?
|
| Dermatitis Herpetiformis | 2 | 2011 | 9 | 0.700 |
Why?
|
| Tissue Embedding | 1 | 2020 | 6 | 0.670 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2020 | 24 | 0.670 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 103 | 0.620 |
Why?
|
| beta Catenin | 1 | 2020 | 266 | 0.580 |
Why?
|
| Chemexfoliation | 1 | 2017 | 3 | 0.550 |
Why?
|
| Dermabrasion | 1 | 2017 | 3 | 0.550 |
Why?
|
| Isotretinoin | 1 | 2017 | 20 | 0.540 |
Why?
|
| Carcinoma in Situ | 1 | 2018 | 53 | 0.540 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 553 | 0.520 |
Why?
|
| Regenerative Medicine | 1 | 2017 | 28 | 0.510 |
Why?
|
| Immunotherapy | 1 | 2022 | 766 | 0.500 |
Why?
|
| Dermatologic Agents | 1 | 2017 | 77 | 0.500 |
Why?
|
| Humans | 46 | 2025 | 96112 | 0.460 |
Why?
|
| Patient Safety | 1 | 2017 | 223 | 0.450 |
Why?
|
| Dapsone | 2 | 2011 | 11 | 0.440 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 6 | 0.440 |
Why?
|
| Cellulitis | 1 | 2014 | 19 | 0.440 |
Why?
|
| Stem Cells | 1 | 2017 | 394 | 0.430 |
Why?
|
| Videotape Recording | 1 | 2014 | 50 | 0.430 |
Why?
|
| Internship and Residency | 3 | 2022 | 1134 | 0.420 |
Why?
|
| Psoriasis | 2 | 2014 | 254 | 0.410 |
Why?
|
| Biopsy | 4 | 2024 | 1220 | 0.370 |
Why?
|
| Botulinum Toxins | 1 | 2021 | 17 | 0.360 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2011 | 5 | 0.350 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2011 | 9 | 0.350 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2011 | 16 | 0.340 |
Why?
|
| Panniculitis | 1 | 2011 | 11 | 0.340 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1798 | 0.340 |
Why?
|
| Hair | 2 | 2010 | 56 | 0.330 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2010 | 5 | 0.330 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 91 | 0.320 |
Why?
|
| Dermatitis | 1 | 2010 | 35 | 0.310 |
Why?
|
| Malnutrition | 1 | 2010 | 36 | 0.310 |
Why?
|
| Consensus | 2 | 2024 | 370 | 0.280 |
Why?
|
| Clinical Competence | 1 | 2014 | 854 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 1021 | 0.280 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 458 | 0.270 |
Why?
|
| Prospective Studies | 7 | 2024 | 4672 | 0.240 |
Why?
|
| Keratinocytes | 3 | 2006 | 146 | 0.240 |
Why?
|
| Dermatofibrosarcoma | 1 | 2025 | 14 | 0.220 |
Why?
|
| Research Support as Topic | 1 | 2025 | 92 | 0.220 |
Why?
|
| Neurotoxins | 2 | 2015 | 48 | 0.220 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 17 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2024 | 136 | 0.210 |
Why?
|
| Male | 16 | 2024 | 45871 | 0.210 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2003 | 6 | 0.200 |
Why?
|
| Skin Diseases | 2 | 2017 | 176 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1096 | 0.190 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2418 | 0.190 |
Why?
|
| Female | 16 | 2024 | 50045 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 580 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 7230 | 0.190 |
Why?
|
| Methylation | 1 | 2023 | 295 | 0.190 |
Why?
|
| Paget Disease, Extramammary | 1 | 2022 | 8 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 422 | 0.180 |
Why?
|
| Prognosis | 3 | 2022 | 4029 | 0.180 |
Why?
|
| Middle Aged | 12 | 2024 | 28371 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2025 | 408 | 0.170 |
Why?
|
| Rubber | 1 | 2020 | 6 | 0.170 |
Why?
|
| Adhesives | 1 | 2020 | 5 | 0.170 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1829 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2025 | 441 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 45 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2024 | 9176 | 0.160 |
Why?
|
| Societies, Medical | 2 | 2022 | 644 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 307 | 0.160 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2019 | 2 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2023 | 3110 | 0.160 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2019 | 8 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2003 | 469 | 0.150 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2019 | 7 | 0.150 |
Why?
|
| Papilloma | 1 | 2019 | 23 | 0.150 |
Why?
|
| RNA | 1 | 2023 | 605 | 0.150 |
Why?
|
| Aged | 11 | 2024 | 20972 | 0.140 |
Why?
|
| Immunocompetence | 1 | 2018 | 27 | 0.140 |
Why?
|
| Lipectomy | 1 | 2017 | 9 | 0.140 |
Why?
|
| Physical Examination | 2 | 2024 | 154 | 0.130 |
Why?
|
| Platelet-Rich Plasma | 1 | 2017 | 13 | 0.130 |
Why?
|
| Cicatrix | 1 | 2017 | 72 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 147 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1619 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2025 | 1773 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 190 | 0.120 |
Why?
|
| Adipocytes | 1 | 2017 | 170 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 3927 | 0.120 |
Why?
|
| Preservation, Biological | 1 | 2015 | 4 | 0.110 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2015 | 16 | 0.110 |
Why?
|
| Injections | 2 | 2021 | 126 | 0.110 |
Why?
|
| Drug Storage | 1 | 2015 | 4 | 0.110 |
Why?
|
| Darier Disease | 1 | 2015 | 5 | 0.110 |
Why?
|
| Drug Contamination | 1 | 2015 | 12 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2017 | 202 | 0.110 |
Why?
|
| Ear, External | 1 | 2015 | 25 | 0.110 |
Why?
|
| Eyebrows | 1 | 2015 | 10 | 0.110 |
Why?
|
| Lasers, Solid-State | 1 | 2015 | 8 | 0.110 |
Why?
|
| Low-Level Light Therapy | 1 | 2015 | 15 | 0.110 |
Why?
|
| Chickenpox | 1 | 2015 | 37 | 0.110 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 28 | 0.110 |
Why?
|
| Exanthema | 1 | 2015 | 41 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.110 |
Why?
|
| Standard of Care | 1 | 2015 | 70 | 0.110 |
Why?
|
| Viscosupplements | 1 | 2013 | 5 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2017 | 777 | 0.100 |
Why?
|
| Forehead | 1 | 2013 | 15 | 0.100 |
Why?
|
| Cetuximab | 1 | 2014 | 119 | 0.100 |
Why?
|
| Skin Aging | 1 | 2013 | 32 | 0.100 |
Why?
|
| Leg | 1 | 2014 | 143 | 0.100 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 53 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 238 | 0.100 |
Why?
|
| Vacuum Curettage | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hyperhidrosis | 1 | 2013 | 10 | 0.100 |
Why?
|
| Operating Rooms | 1 | 2014 | 138 | 0.100 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 133 | 0.100 |
Why?
|
| Neutrophils | 1 | 2014 | 332 | 0.100 |
Why?
|
| Microinjections | 1 | 2012 | 71 | 0.090 |
Why?
|
| Needles | 1 | 2012 | 42 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1218 | 0.090 |
Why?
|
| Serologic Tests | 1 | 2011 | 43 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 237 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2021 | 111 | 0.080 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 91 | 0.080 |
Why?
|
| Face | 1 | 2021 | 115 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 232 | 0.080 |
Why?
|
| Diet, Gluten-Free | 1 | 2011 | 60 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 198 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 96 | 0.080 |
Why?
|
| Microscopy | 1 | 2010 | 91 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 873 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 481 | 0.070 |
Why?
|
| Adult | 7 | 2024 | 28725 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 271 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1981 | 0.070 |
Why?
|
| Transcription Factor AP-2 | 2 | 2006 | 14 | 0.070 |
Why?
|
| Time Factors | 2 | 2015 | 5585 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2011 | 307 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2011 | 276 | 0.070 |
Why?
|
| Celiac Disease | 1 | 2011 | 219 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2883 | 0.070 |
Why?
|
| Comorbidity | 1 | 2011 | 1011 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1973 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2018 | 10287 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2614 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2024 | 50 | 0.050 |
Why?
|
| Uncertainty | 1 | 2024 | 82 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2015 | 162 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2024 | 36 | 0.050 |
Why?
|
| Phenotype | 1 | 2010 | 2579 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 44 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 54 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2010 | 3974 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2006 | 513 | 0.050 |
Why?
|
| Equipment Design | 2 | 2015 | 427 | 0.050 |
Why?
|
| Private Practice | 1 | 2022 | 12 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 296 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2474 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 86 | 0.040 |
Why?
|
| Patient Care | 1 | 2022 | 101 | 0.040 |
Why?
|
| Animals | 5 | 2011 | 28919 | 0.040 |
Why?
|
| Cell Division | 1 | 2003 | 705 | 0.040 |
Why?
|
| Young Adult | 4 | 2015 | 7025 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2003 | 446 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2003 | 1267 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 124 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2002 | 308 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2003 | 1667 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1179 | 0.040 |
Why?
|
| Mesotherapy | 1 | 2017 | 2 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1471 | 0.030 |
Why?
|
| Deoxycholic Acid | 1 | 2017 | 13 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 615 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2017 | 30 | 0.030 |
Why?
|
| Photography | 1 | 2017 | 38 | 0.030 |
Why?
|
| Ultrasonic Therapy | 1 | 2017 | 44 | 0.030 |
Why?
|
| Mice | 4 | 2006 | 12541 | 0.030 |
Why?
|
| United States | 2 | 2024 | 7768 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 3581 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2860 | 0.030 |
Why?
|
| Keratins | 2 | 2006 | 63 | 0.030 |
Why?
|
| Gloves, Surgical | 1 | 2013 | 7 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2013 | 19 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 475 | 0.030 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 25 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 48 | 0.030 |
Why?
|
| Universities | 1 | 2013 | 154 | 0.020 |
Why?
|
| Axilla | 1 | 2013 | 110 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 56 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 240 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2012 | 61 | 0.020 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 36 | 0.020 |
Why?
|
| Wound Healing | 1 | 2013 | 378 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 118 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 97 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 996 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 9895 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1715 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 1645 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 463 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1791 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 847 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2006 | 7 | 0.020 |
Why?
|
| Chromones | 1 | 2006 | 31 | 0.020 |
Why?
|
| Hair Diseases | 1 | 2006 | 9 | 0.020 |
Why?
|
| Skin Abnormalities | 1 | 2006 | 12 | 0.020 |
Why?
|
| Dermis | 1 | 2006 | 30 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2006 | 50 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 67 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 133 | 0.010 |
Why?
|
| Integrases | 1 | 2006 | 67 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 116 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2006 | 164 | 0.010 |
Why?
|
| Morpholines | 1 | 2006 | 77 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 142 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 156 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 2061 | 0.010 |
Why?
|
| Epidermis | 1 | 2006 | 104 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 224 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 206 | 0.010 |
Why?
|
| Quinazolines | 1 | 2006 | 216 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 535 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 367 | 0.010 |
Why?
|
| Hair Follicle | 1 | 2003 | 29 | 0.010 |
Why?
|
| GATA3 Transcription Factor | 1 | 2003 | 52 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 1157 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3652 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 657 | 0.010 |
Why?
|
| Sp2 Transcription Factor | 1 | 2002 | 1 | 0.010 |
Why?
|
| Keratin-5 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Keratin-15 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2002 | 24 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 2002 | 30 | 0.010 |
Why?
|
| Sebaceous Glands | 1 | 2002 | 28 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2002 | 175 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2003 | 193 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1320 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 1205 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 1333 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1755 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 1167 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 2344 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3040 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1192 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 2940 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 1730 | 0.010 |
Why?
|